Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Director Sells $23,932.32 in Stock

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Director Corazon (Corsee) D. Sanders sold 584 shares of the company’s stock in a transaction on Tuesday, July 2nd. The shares were sold at an average price of $40.98, for a total value of $23,932.32. Following the sale, the director now owns 12,009 shares of the company’s stock, valued at $492,128.82. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Ultragenyx Pharmaceutical Price Performance

Shares of Ultragenyx Pharmaceutical stock traded down $0.75 on Wednesday, hitting $40.21. 638,254 shares of the company’s stock traded hands, compared to its average volume of 823,300. Ultragenyx Pharmaceutical Inc. has a one year low of $31.52 and a one year high of $54.56. The company has a fifty day moving average of $41.16 and a two-hundred day moving average of $44.99. The company has a market capitalization of $3.34 billion, a price-to-earnings ratio of -5.01 and a beta of 0.56.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($2.03) EPS for the quarter, missing the consensus estimate of ($1.72) by ($0.31). Ultragenyx Pharmaceutical had a negative net margin of 138.58% and a negative return on equity of 425.63%. The business had revenue of $108.83 million for the quarter, compared to the consensus estimate of $116.03 million. During the same quarter in the previous year, the company earned ($2.33) EPS. The firm’s revenue for the quarter was up 8.3% on a year-over-year basis. Equities research analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -6.43 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts have recently commented on RARE shares. Canaccord Genuity Group boosted their price target on Ultragenyx Pharmaceutical from $109.00 to $111.00 and gave the stock a “buy” rating in a report on Friday, May 31st. TD Cowen upped their target price on Ultragenyx Pharmaceutical from $59.00 to $61.00 and gave the stock a “buy” rating in a report on Wednesday, April 24th. Bank of America lowered their target price on Ultragenyx Pharmaceutical from $83.00 to $76.00 and set a “buy” rating for the company in a report on Friday, May 31st. The Goldman Sachs Group raised Ultragenyx Pharmaceutical from a “neutral” rating to a “buy” rating and upped their target price for the stock from $56.00 to $67.00 in a report on Thursday, June 6th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $115.00 target price on shares of Ultragenyx Pharmaceutical in a report on Wednesday, June 12th. Two equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $86.71.

Institutional Trading of Ultragenyx Pharmaceutical

Institutional investors and hedge funds have recently modified their holdings of the stock. Franklin Resources Inc. raised its stake in shares of Ultragenyx Pharmaceutical by 13.3% in the fourth quarter. Franklin Resources Inc. now owns 214,738 shares of the biopharmaceutical company’s stock worth $10,269,000 after purchasing an additional 25,144 shares during the last quarter. Rafferty Asset Management LLC increased its position in shares of Ultragenyx Pharmaceutical by 21.2% during the fourth quarter. Rafferty Asset Management LLC now owns 221,910 shares of the biopharmaceutical company’s stock valued at $10,612,000 after acquiring an additional 38,859 shares during the last quarter. New York State Common Retirement Fund increased its position in shares of Ultragenyx Pharmaceutical by 37.0% during the fourth quarter. New York State Common Retirement Fund now owns 72,866 shares of the biopharmaceutical company’s stock valued at $3,484,000 after acquiring an additional 19,673 shares during the last quarter. DekaBank Deutsche Girozentrale increased its position in shares of Ultragenyx Pharmaceutical by 42.5% during the fourth quarter. DekaBank Deutsche Girozentrale now owns 57,000 shares of the biopharmaceutical company’s stock valued at $2,745,000 after acquiring an additional 17,000 shares during the last quarter. Finally, Vanguard Group Inc. increased its position in shares of Ultragenyx Pharmaceutical by 19.9% during the fourth quarter. Vanguard Group Inc. now owns 8,673,432 shares of the biopharmaceutical company’s stock valued at $414,764,000 after acquiring an additional 1,440,264 shares during the last quarter. 97.67% of the stock is owned by hedge funds and other institutional investors.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.